PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Mov Disord. Author manuscript; available in PMC Nov 15, 2011.
Published in final edited form as:
PMCID: PMC2978754
NIHMSID: NIHMS207952
CSF Aβ42 and tau in Parkinson’s disease with cognitive impairment
Thomas J. Montine,1 Min Shi,1 Joseph F. Quinn,2 Elaine R. Peskind,3,4 Suzanne Craft,3,5 Carmen Ginghina,1 Kathryn A. Chung,2 Hojoong Kim,5,8 Douglas R. Galasko,6 Joseph Jankovic,7 Cyrus P. Zabetian,5,8 James B. Leverenz,4,8 and Jing Zhang1
1Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA
2Department of Neurology, Oregon Health & Science University, Portland, OR, USA
3Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA
4VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA
5Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA
6Department of Neurosciences, University of California at San Diego, San Diego, CA, USA
7Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
8Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA
Corresponding author: Thomas J. Montine, MD, PhD; Department of Pathology; University of Washington; 300 9th Ave, Room 713B; Seattle WA, 98104; Phone: 206-744-6776; Fax: 206-897-5249; tmontine/at/uw.edu
Authors contributed equally
Author Roles.* Montine: 1a,b, 2a-c,3a,b; Shi:1c,3b; Quinn 1b,c, 3b; Peskind 1b,c, 3b; Craft 1b,c, 2c, 3b; Ginghina 1c, 3b; Chung 1b,c, 3b; Kim 1b,c, 3b; Galasko 1b,c, 2c,3b; Jankovic 1b,c, 3b; Zabetian 1b,c, 3b; Leverenz 1b,c, 3b; and Zhang 1a,b, 3b.
*Key: 1. Research project: a. Conception, b. Organization, c. Execution; 2. Statistical Analysis: a. Design, b. Execution, c. Review and Critique; 3. Manuscript: a. Writing of the first draft, b. Review and Critique.
We tested the hypothesis that the CSF biomarker signature associated with Alzheimer’s disease (AD) is present in a subset of individuals with Parkinson’s disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ42, total tau (T-tau), and phospho-tau (P181-Tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤ 50 years (35), Controls > 50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ42 was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01) while average CSF T-Tau and P181-Tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ42 may be a common feature of PD-CIND and PD-D.
Keywords: Parkinson’s disease, cognitive impairment, CSF biomarkers, Aβ42, tau
Recent focus on biomarkers for Alzheimer’s disease (AD) is fueled by now abundant data showing that processes of this disease start years prior to dementia or less severe forms of cognitive impairment (CI); the latter is commonly defined clinically as amnestic Mild CI (aMCI).1 Currently, the most successful biomarker candidates for AD are PET imaging for fibrillar amyloid beta (Aβ), structural MRI, and quantification of cerebrospinal fluid (CSF) Aβ42, total tau (T-tau), and tau phosphorylated at amino acid 181 (P181-tau; reviewed in 2). Indeed, increased CSF T-tau and P181-tau and decreased CSF Aβ42 are characteristic of AD or aMCI in cross-sectional studies (reviewed in 2 and 3), and similar changes are present in older individuals without CI who are at increased risk of conversion to MCI or AD.4-7 Emerging data suggest that neuroimaging and quantification of these CSF proteins are comparable in detecting processes of AD in preclinical settings.7-9
Parkinson’s disease (PD) is now recognized commonly to include dementia (PD-D) and less severe forms of CI; in the PD research community the latter is commonly defined by a set of clinical criteria for “CI, Not Dementia” (CIND).10 Indeed, the point prevalence of dementia among patients with PD is approximately one-third, and approximately 75% of patients with PD develop dementia over 10 years.11 Several hypotheses for CI in PD have been proposed, including subcortical processes, extension of Lewy body disease from brainstem to isocortical structures, and co-morbid AD; however, the extent to which each or a combination of these processes contributes CI in PD is unclear. The ability to identify patients with PD-CIND or PD-D deriving from AD versus other causes of dementia likely will be critical to organizing clinical trials and managing patients once disease-modifying therapies are developed. This issue has been addressed only in a few individuals by neuroimaging12 and in CSF-based studies of limited number of relatively small disease groups that yielded conflicting conclusions.13, 14 Here we quantified CSF Aβ42, T-tau, and P181-tau in 345 individuals to estimate the prevalence of co-morbid AD among patients with PD who did or did not have CI at the time of lumbar puncture.
The Human Subject Institutional Review Boards of Baylor College of Medicine, Oregon Health & Science University, the University of California at San Diego, VA Puget Sound Health Care System, and the University of Washington approved this study. All individuals provided informed consent, and underwent evaluation that consisted of medical history, physical and neurologic examinations, laboratory tests, and neuropsychological assessment. Laboratory evaluation included complete blood count (serum electrolytes, blood urea nitrogen, creatinine, glucose, vitamin B12, and thyroid stimulating hormone); all results were within normal limits. Exclusion criteria included moderate or heavy cigarette smoking (more than 10 packs/year), alcohol use other than social, and any psychotherapeutic drug use other than for treatment of AD or PD.
Controls were healthy volunteers who had normal cognitive performance on a battery of neuropsychological tests at the time of lumbar puncture as previously described. 15 All controls had at least one year of follow-up (median of 3 years) without demonstrating any symptoms or signs of neurologic disease. AD16, PD17, and aMCI1 were diagnosed by established criteria. The diagnosis of PD-D was determined by established criteria10 and included the “one-year rule” for differentiation from Dementia with Lewy Bodies, viz., dementia must occur one year after onset of motor parkinsonism in PD-D. The diagnosis of PD-CIND was made in subjects with a diagnosis of PD and a clinical dementia rating of 0.518 but without dementia as determined by PD-D criteria.
All CSF was obtained by lumbar puncture in the morning, was free of visual contamination by blood, had hemoglobin levels < 6.0 μg/ml, and was flash frozen and then stored at −80°C in polypropylene cryovials until used.19 All CSF samples from individuals in research cohorts at our institutions that met the above criteria were assayed for T-tau, P181-tau, and Aβ42 concentrations using AlzBio3 Luminex kits from Innogenetics (Alpharetta, GA) by following exactly the manufacturer’s instructions and were within the range of values reported by others.4, 7 Coded samples were analyzed by individuals who did not know any corresponding clinical information. Statistical analyses were performed with GraphPad Prism (San Diego, CA).
In order to match age among disease groups and individuals with aMCI, we excluded 12 PD patients who were ≤ 50 years of age and divided Controls into ≤ or > 50 years old. There was no significant difference in concentrations (pg/ml) of any of the three CSF analytes between Controls > 50 yr and Controls ≤ 50 yr. Table 1 summarizes data from the remaining 333 CSF samples used in primary analyses. As expected, the AD group had significantly decreased CSF Aβ42 (P < 0.001) and significantly increased CSF T-tau (P < 0.001) and P181-tau (P < 0.001) concentrations compared to Controls > 50 yr. Similar to others, we observed increased CSF T-tau (P < 0.05) and P181-tau (P < 0.001) concentrations in individuals with aMCI.4, 7 Figure 1A plots individuals’ CSF Aβ42 vs. P181-tau levels for both Control groups, aMCI, and AD.
Table 1
Table 1
Age and Biomarker Results for Each Group
Figure 1
Figure 1
Scatter plots of CSF Aβ42 and P181-tau concentrations
CSF P181-tau/Aβ42 is a convenient means to summarize the coincidental increase in CSF P181-tau and decrease in CSF Aβ42 that is characteristic of AD. Assuming that clinically silent AD is uncommon in Controls ≤ 50 years, we and others have previously used this ratio in Controls ≤ 50 years to define an upper cutoff value for normal CSF P181-tau/Aβ42.5, 6 Using this approach, 3% of Controls ≤ 50 years, 25% of Controls > 50 years, 92% of individuals with aMCI, and 96% of patients with AD had abnormally increased CSF P181-tau/Aβ42. Similar results were obtained using CSF T-tau/ Aβ42 (not shown). These results validated this method for detecting pre-clinical and clinical AD.
Among the groups of patients with PD, CSF Aβ42 levels ranged from normal in those without CI, to progressively lower values in patients with PD-CIND (P < 0.05) or PD-D (P < 0.01). In contrast to patients with aMCI or AD, CSF T-tau levels were unchanged in the three PD groups and CSF P181-tau levels were significantly decreased in patients with PD (P < 0.05) or PD-CIND (P < 0.01). Figure 1B plots individuals’ CSF Aβ42 vs. P181-tau to display the strikingly different biomarker signature among patients with PD, PD-CIND, or PD-D compared to patients with aMCI or AD. Using the same approach as above, we estimated that 15% of patients with PD, 29% of patients with PD-CIND, and 45% of patients with PD-D had abnormally elevated CSF P181-tau/Aβ42.
Unlike MCI and both groups with dementia, there were eight patients (age range) with PD (35 to 50 years) and four patients with PD-CIND (40 to 50 years) who were ≤ 50 years old. None of the CSF concentrations for any of the three analytes was out of the range reported for the corresponding group of older patients.
Quantification of CSF Aβ42, T-tau, and P181-tau provides a validated means to assess processes of AD in patients with dementia or CI, and even in older individuals who are cognitively normal.2-9 Applying this tool to 119 patients with PD and a spectrum of CI, we observed progressively lower CSF Aβ42 concentrations in patients with PD, PD-CIND, or PD-D. In combination with exquisite studies of others,8 these data suggest that progressive CI in patients with PD may be associated with increased deposition of fibrillar Aβ in cerebrum, and that this process might be demonstrable with PET imaging.9
T-tau increases in CSF in AD and other degenerative and destructive diseases of brain and is widely thought to signify damage to neurons. Although CSF T-tau levels trended to lower values in the PD-D group, these were not significant and thereby concordant with the results of some14 but not others who observed an increase in average CSF T-tau in patients with PD-D.13 In contrast, we observed that average P181-tau concentrations in PD and PD-CIND groups were significantly 20% lower than age-matched controls and this result differs from others who have reported no difference or increased average CSF P181-tau in these groups.13, 14 CSF P181-tau is more difficult to interpret than T-tau since its levels presumably reflect at least two potentially related mechanisms, cellular processes that lead to phosphorylation and release from damaged neurons. The reasons for these discrepant results among studies are not clear. However, one interpretation of our results is that patients with PD, PD-CIND, and PD-D may have less neuron damage than patients with aMCI or AD and may have suppression of those biochemical processes that lead to theronine-181 phosphorylation on tau.
We estimated that approximately one-third of patients with PD-CIND and slightly less than one-half of patients with PD-D had abnormally increased CSF P181-tau/Aβ42, although there was no distinct pattern of sub-populations (see Figure 1B). This stands in sharp contrast to the > 90% of patients with aMCI or AD who had abnormally increased CSF P181-tau/Aβ42. One possible explanation for these results is that the majority of patients with PD and CI do not have co-morbid AD.
Our results suggest that validated CSF biomarkers for processes of AD may be helpful in identifying those patients with PD and co-morbid AD. Further investigation of the neuropsychological profile and possible risk from inheritance of the ε4 allele of APOE is needed for this group of patients with PD and CI. However, our results also indicate that this is a minority of patients with PD-CIND or PD-D, and underscore the need for further research into other more common causes of CI and dementia in patients with PD.
Acknowledgements
This work was supported by grants from the NIH (ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, AG08017 and AG08671), the Michael J. Fox Foundation, and the Nancy and Buster Alvord Endowment. This support had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. We thank Dr. Kathleen Montine for editorial assistance.
Financial Disclosure: This work was supported by grants from the NIH (ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, AG08017 and AG08671), the Michael J. Fox Foundation, and the Nancy and Buster Alvord Endowment. This support had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Full Financial Disclosure of all Authors for the Past Year. Financial support was received from the NIH, the VA, and the Michael J. Fox Foundation.
Footnotes
Conflict of Interest: No author had a conflict of interest.
1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. [PubMed]
2. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, Montine TJ. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol. 2008;7:704–714. [PMC free article] [PubMed]
3. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–413. [PMC free article] [PubMed]
4. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–393. [PubMed]
5. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631–639. [PubMed]
6. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343–349. [PubMed]
7. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294–301. [PMC free article] [PubMed]
8. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med. 2009;1:371–380. [PMC free article] [PubMed]
9. Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of PIttsburgh Compound B Detection of CerebralAmyloid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal FluidMarkers of Alzheimer Disease. Arch Neurol. 2009;66:1557–1562. [PMC free article] [PubMed]
10. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–1707. quiz 1837. [PubMed]
11. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010;289:18–22. [PubMed]
12. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010;74:77–84. [PMC free article] [PubMed]
13. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord. 2009;24:2203–2210. [PubMed]
14. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008;64:850–855. [PubMed]
15. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129:526–529. [PMC free article] [PubMed]
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944. [PubMed]
17. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–752. [PMC free article] [PubMed]
18. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414. [PubMed]
19. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010;133:713–726. [PMC free article] [PubMed]